ReviewInternational journal of cardiology. Cardiovascular risk and prevention2025
Circulating-free DNA: A promising tool for early detection of myocardial infarction.
Review in International journal of cardiology. Cardiovascular risk and prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Liquid biopsy: current applications and future directions.Molecular biomedicine · 2026Review
- Preliminary exploration of dynamic changes in circulating mitochondrial DNA (ΔmtDNA) as a prognostic biomarker for acute ST-segment elevation myocardial infarction patients: a prospective observational study.BMC cardiovascular disorders · 2026Observational
- Fecal Immunochemical Test and Multitarget Stool DNA Testing for Colorectal Cancer Screening in Real-World Practice: A Literature Review.Journal of clinical medicine · 2026Review
- Cell-free DNA methylation-based detection of organ damage following proton versus photon radiotherapy: a case series.Translational pediatrics · 2026Article
- Circulating-free DNA and myocardial infarction: From diagnostic promise to clinical translation.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Molecular characterization of cell decay in inflammation and topological assignment of released cfDNA for integrative laboratory and radiological outcome assessment.Frontiers in cellular and infection microbiology · 2025Article
- Case Report: Single-cell RNA sequencing reveals cellular and molecular mechanisms in newborn cardiac hemangioma formation.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction (MI) is a leading global cause of mortality, necessitating novel biomarkers for early diagnosis and prognosis. This review explores circulating cell-free DNA (cfDNA) as a minimally invasive tool for MI detection, focusing on its mechanistic role, diagnostic accuracy, and potential in personalized medicine. CfDNA levels rise rapidly post-ischemic event, correlating with myocardial damage and complementing troponins. Liquid biopsies using cfDNA enable dynamic monitoring of disease progression, but methodological variability and low concentrations limit its standalone use. Standardizing protocols and integrating cfDNA into multi-marker panels could enhance its clinical utility, positioning it as a transformative cardiovascular diagnostic tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.